ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1976

Ultrasound Inflammation in Patients Presenting with Arthralgia Is Associated with Developing Arthritis

Myrthe van der Ven1, Marjolein Van der Veer-Meerkerk1, David F. Ten Cate2, Nigara Rasappu3, Marc R. Kok4, Dora Csakvari5, Johanna M.W. Hazes2, Andreas H. Gerards6 and Jolanda J. Luime3, 1Rheumatology, Erasmus University Medical Centre, Rotterdam, Netherlands, 2Department of Rheumatology, Erasmus University Medical Centre, Rotterdam, Netherlands, 3Rheumatology, Erasmus Medical Centre, Rotterdam, Netherlands, 4Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, 5Rheumatology, Erasmus University Medical Centre, ROTTERDAM, Netherlands, 6Rheumatology, Vlietland Hospital, Schiedam, Netherlands

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: anti-CCP antibodies, arthritis and ultrasonography

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Title: Imaging of Rheumatic Diseases II: Ultrasound in Rheumatoid Arthritis

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: To further decrease the burden of RA we need to identify patients early, preferably in absence of clinical apparent synovitis. Recent studies in US suggest that earlier detection is possible. We aim to identify arthralgia patients developing clinical apparent inflammatory arthritis (IA) within a year using US to detect subclinical synovitis at first consultation.

Methods: We followed arthralgia patients with at least two painful joints of hands, feet or shoulders without clinical apparent synovitis over one year in a multi-centre cohort study. Their symptoms needed to be present <1 year and were not explained by other conditions (e.g. fibromyalgia). We collected data at baseline, 6 months and 12 months follow-up including physical examination, laboratory variables (ESR, CRP, auto-antibodies), diagnosis and medication. At baseline we also examined 26 joints (bilateral MCP2-5, PIP2-5, wrist, MTP2-5) by US and images were scored semi-quantitatively on greyscale (GS; 0-3) and power Doppler (PD; 0-3). US synovitis was defined as GS grade 2 or 3 and/or presence of PD. One-year incident IA was defined as clinical soft tissue swelling. Univariate logistic regression was used to analyse the association between demographic characteristics, clinical characteristics, and US findings and the incidence of IA for all patients. This was then further explored selecting the strongest variables (p<0.157) in a multivariate logistic regression. Missing values in independent variables were imputed using STATA (multiple imputation by chained equations (m=5)).

Results: In total, 196 patients were included of whom 160 completed the 12 months follow-up. At baseline 71 (37%) arthralgia patients had US synovitis and in 29 (15%) patients PD signal was detected. Incident IA was present in 37 (19%) patients (Table 1: baseline characteristics) of whom 22 patients initiated DMARD treatment during the one-year follow-up. Strongest associations in the univariate analysis were found for RF (OR 2.4), morning stiffness >30 minutes (OR 2.9), ACPA (OR 3.8), US synovitis (OR 2.1) and PD signal (OR 4.8). In the multivariate logistic regression the presence of morning stiffness >30 minutes (OR 3.7: 95%CI 1.4-9.5), ACPA (OR 4.0: 95%CI 1.5-10.6) and PD signal (OR 4.3: 95%CI 1.7-10.9) were associated with incident IA (Table 2).

Conclusion: One-year incident IA was present in 19% of the early arthralgia patients of which 53% showed US synovitis at baseline. The presence of PD signal, morning stiffness >30 minutes and ACPA were significantly associated with the development of IA after one year.

 

Table 1 Baseline characteristics (n=194)
IA patients (n=37) Non-IA patients (n=157) p-value*
Women, n (%) 30 (81) 127 (80) 0.923
Age, years, mean (sd) 44 (11) 45 (12) 0.742
BMI, mean (sd) 26.7 (4.6) 27.3 (5.1) 0.476
SJC44, median (IQR) 0 (0-0) 0 (0-0) –
TJC44, median (IQR) 4 (3-8) 5 (3-7) 0.979
RF positive, n (%) 14 (40) 34 (22) 0.031
ACPA positive, n (%) 12 (34) 18 (12) 0.001
ESR, median (IQR) 11 (6-24) 10 (5-19) 0.298
CRP, median (IQR) 2 (1-14) 3 (1-8) 0.917
Morning stiffness, minutes, median (IQR) 60 (30-90) 30 (15-60) 0.033
DAS28, mean (sd) 3.5 (1.1) 3.2 (1.0) 0.171
US synovitis, n (%) 20 (54) 52 (34) 0.039
PD score >0, n (%) 14 (38) 16 (11) <0.001

IA: inflammatory arthritis; BMI: body mass index; SJC44: swollen joint count in 44 joints; TJC44: tender joint count in 44 joints; RF: rheumatoid factor; ACPA: anti-citrullinated protein antibody; DAS44: disease activity score in 44 joints; US: ultrasound; PD: power Doppler; IQR: interquartile range; sd: standard deviation; *Depending on the distribution of the data, we used the independent t test or the Wilcoxon-Mann-Whitney test, frequencies were compared using a Chi2 test, p-value≤0.05

 

Table 2 Univariate logistic regression analyses and multivariate logistic regression analysis after multiple imputation (n=194)  

Univariate model

Multivariate model 1

US synovitis

Multivariate model 2

Presence of PD

OR (95% CI)

p-value

OR (95% CI)

p-value

OR (95% CI)

p-value

 
Demographics

 

 

 

Age, years

0.99 (0.96-1.03)

0.732

 

 

 

Sex

1.05 (0.42-2.62)

0.909

 

 

 

BMI

0.97 (0.89-1.04)

0.384

 

 

 

 

 
Clinical variables

 

 

 

Tender joints, range 0-44

1.00 (0.92-1.08)

0.959

 

 

 

DAS28

1.39 (0.97-1.99)

0.077

 

 

 

 

 

Morning stiffness >30 minutes

2.85 (1.21-6.70)

0.016

3.64 (1.41-9.39)

0.007

3.67 (1.42-9.50)

0.007

 

Rheumatoid factor positive

2.35 (1.08-5.12)

0.032

 

 

 

 

ACPA positive

3.79 (1.61-8.90)

0.002

4.89 (1.90-12.55)

0.001

3.98 (1.50-10.56)

0.006

 

CRP

1.00 (0.98-1.03)

0.754

 

 

 

 

 

ESR

1.02 (0.99-1.04)

0.180

 

 

 

 

 
Ultrasound

 

 

 

US positive

2.13 (1.02-4.44)

0.044

2.23 (1.41-4.90)

0.045

 

 

 

PD positive

4.80 (2.05-11.28)

<0.001

 

 

4.26 (1.67-10.86)

0.002

 
BMI: body mass index; ACPA: anti-citrullinated protein antibody; US: ultrasound; PD: power Doppler; OR: odds ratio  

 


Disclosure: M. van der Ven, None; M. Van der Veer-Meerkerk, None; D. F. Ten Cate, None; N. Rasappu, None; M. R. Kok, None; D. Csakvari, None; J. M. W. Hazes, None; A. H. Gerards, None; J. J. Luime, None.

To cite this abstract in AMA style:

van der Ven M, Van der Veer-Meerkerk M, Ten Cate DF, Rasappu N, Kok MR, Csakvari D, Hazes JMW, Gerards AH, Luime JJ. Ultrasound Inflammation in Patients Presenting with Arthralgia Is Associated with Developing Arthritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/ultrasound-inflammation-in-patients-presenting-with-arthralgia-is-associated-with-developing-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/ultrasound-inflammation-in-patients-presenting-with-arthralgia-is-associated-with-developing-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology